Skip to main content
PMC home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 1999 Nov;49(448):892–896.

Newer antidepressants: a comparison of tolerability in general practice.

F R Mackay, N R Dunn, R M Martin, G L Pearce, S N Freemantle, R D Mann
PMCID: PMC1313560  PMID: 10818655

Abstract

BACKGROUND: An increasing number of antidepressants have been released on the United Kingdom market in recent years, and these are being prescribed more frequently in general practice. Clinical trials suggest that such agents have similar efficacy and the choice of drug is probably based on tolerability, toxicity in overdose, and cost. AIM: To compare the tolerability and safety profile of six, newly marketed antidepressants used in general practice. METHOD: Studies have been conducted for six antidepressants: fluoxetine, sertraline, paroxetine, moclobemide, venlafaxine, and nefazodone, using the technique of prescription-event monitoring. Patients were identified using incident dispensed prescription data. Questionnaires were sent to patients' general practitioners six months after the date of first prescription. Questionnaires asked for date of birth, sex, indication for prescribing each drug, and all events entered in the patients' records after the date of first prescription. RESULTS: Each cohort exceeded 10,000 patients. Nausea/vomiting was the most frequently reported event for all drugs. The difference in incidence rates for drowsiness/sedation, male sexual dysfunction, and hypertension is shown. Mortality data are also reported. CONCLUSION: Frequently reported events were similar for all six drugs but there were clinically and statistically significant differences for less frequently reported events. The adjusted mortality rate was identical between the six drugs. This study provides valuable comparative data for six, widely used antidepressants in general practice.

Full Text

The Full Text of this article is available as a PDF (51.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beardon P. H., McGilchrist M. M., McKendrick A. D., McDevitt D. G., MacDonald T. M. Primary non-compliance with prescribed medication in primary care. BMJ. 1993 Oct 2;307(6908):846–848. doi: 10.1136/bmj.307.6908.846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Donoghue J., Tylee A., Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ. 1996 Oct 5;313(7061):861–862. doi: 10.1136/bmj.313.7061.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eberstein S., Adler L. A., Angrist B. Nefazodone and akathisia. Biol Psychiatry. 1996 Oct 15;40(8):798–799. doi: 10.1016/0006-3223(96)00268-5. [DOI] [PubMed] [Google Scholar]
  4. Feder R. Fluoxetine-induced mania. J Clin Psychiatry. 1990 Dec;51(12):524–525. [PubMed] [Google Scholar]
  5. Freeman H. Moclobemide. Lancet. 1993 Dec 18;342(8886-8887):1528–1532. doi: 10.1016/s0140-6736(05)80090-x. [DOI] [PubMed] [Google Scholar]
  6. Hale A. S. ABC of mental health. Depression. BMJ. 1997 Jul 5;315(7099):43–46. doi: 10.1136/bmj.315.7099.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Inman W., Pearce G. Prescriber profile and post-marketing surveillance. Lancet. 1993 Sep 11;342(8872):658–661. doi: 10.1016/0140-6736(93)91763-c. [DOI] [PubMed] [Google Scholar]
  8. Laux G., Philipp M., Kohnen R. Hypertension with moclobemide. Lancet. 1996 May 11;347(9011):1330–1330. doi: 10.1016/s0140-6736(96)90975-7. [DOI] [PubMed] [Google Scholar]
  9. Mackay F. J., Dunn N. R., Wilton L. V., Pearce G. L., Freemantle S. N., Mann R. D. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):235–246. doi: 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  10. Mann R. D., Wilton L. V., Pearce G. L., Mackay F. J., Dunn N. R. Prescription-event monitoring (PEM) in 1996-a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Saf. 1997 Oct;6 (Suppl 3):S5–11. doi: 10.1002/(SICI)1099-1557(199710)6:3+<S5::AID-PDS272>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  11. Martin R. M., Hilton S. R., Kerry S. M., Richards N. M. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ. 1997 Mar 1;314(7081):646–651. doi: 10.1136/bmj.314.7081.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McAvoy B. R., Kaner E. F. General practice postal surveys: a questionnaire too far? BMJ. 1996 Sep 21;313(7059):732–734. doi: 10.1136/bmj.313.7059.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Paykel E. S., Priest R. G. Recognition and management of depression in general practice: consensus statement. BMJ. 1992 Nov 14;305(6863):1198–1202. doi: 10.1136/bmj.305.6863.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994 Apr;164(4):549–550. doi: 10.1192/bjp.164.4.549. [DOI] [PubMed] [Google Scholar]
  15. Preskorn S. H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56 (Suppl 6):12–21. [PubMed] [Google Scholar]
  16. Song F., Freemantle N., Sheldon T. A., House A., Watson P., Long A., Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993 Mar 13;306(6879):683–687. doi: 10.1136/bmj.306.6879.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Vervloet D., Durham S. Adverse reactions to drugs. BMJ. 1998 May 16;316(7143):1511–1514. doi: 10.1136/bmj.316.7143.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES